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Highly active antiretroviral therapy (HAART) and other medical therapies for HIV-related infections have been associated with
toxicities. Antiretroviral therapy can contribute to renal dysfunction directly by inducing acute tubular necrosis, acute interstitial
nephritis, crystal nephropathy, and renal tubular disorders or indirectly via drug interactions. With the increase in HAART use,
clinicians must screen patients for the development of kidney disease especially if the regimen employed increases risk of kidney
injury. It is also important that patients with chronic kidney disease (CKD) are not denied the best combinations, especially
since most drugs can be adjusted based on the estimated GFR. Early detection of risk factors, systematic screening for chronic
causes of CKD, and appropriate referrals for kidney disease management should be advocated for improved patient care. The
interaction between immunosuppressive therapy and HAART in patients with kidney transplants and the recent endorsement
of tenofovir/emtricitabine by the Centers for Disease Control (CDC) for preexposure prophylaxis bring a new dimension for
nephrotoxicity vigilance. This paper summarizes the common antiretroviral drugs associated with nephrotoxicity with particular
emphasis on tenofovir and protease inhibitors, their risk factors, and management as well as prevention strategies.
1.Introduction
Highly active antiretroviral therapy (HAART) consisting
of at least three drugs active against HIV infection has
revolutionized the management of HIV-AIDS. This has been
reﬂected in the reductions in morbidity and mortality across
the globe [1–3]. However, use of antiretroviral drugs has
been associated with a number of toxicities, including those
aﬀecting the kidney [4]. The kidney plays a major role
in the metabolism and excretion of antiretroviral drugs
and this makes it vulnerable to various types of injuries
from some of these agents, including acute kidney injury
(AKI), tubulopathies, chronic kidney disease (CKD), and
end-stage renal disease requiring renal replacement therapy.
As the population of HIV-infected patients ages and remains
on HAART for longer periods of time, age-, HIV- and
HAART-related metabolic disorders are increasingly being
encountered by clinicians looking after these patients.
This paper reviews recent advances on the HAART-
related nephrotoxicity, with a particular emphasis on early
recognition and management of patients who may be at
increased risk.
2. Epidemiology of Nephropathy in the HIV-
InfectedPopulationsince the HAART Era
Nephropathy in HIV can be caused by both HIV-related
and non-HIV-related pathologies. Non-HIV related causes
include hypertension, diabetes mellitus, atherosclerosis,
drugs,primaryandsecondarynephropathies,aswellasother
infections [5].
HIV can cause direct injury to the kidneys as manifested
by HIV-associated nephropathy (HIVAN). This entity was
described before the era of HAART but continues to be
a signiﬁcant problem despite the advent of HAART [5–
7]. HIVAN is the third leading cause of ESRD in African
A m e r i c a n sw h oa r ea l s o1 8t i m e sm o r el i k e l yt op r o g r e s st o
ESRD than their white American counterparts [8]. A few
years ago, HIVAN was initially considered to be genetically
linked to a variation in the MYH9 locus of chromosome2 AIDS Research and Treatment
22, which is found in 60% of African Americans and in less
than 4% of Europeans [9]. However, recent researchers have
noted that the MYH9 gene is located next to the APOL-1
gene which is more signiﬁcantly associated with ESRD than
all previously reported variations in MYH9 gene [10]. In less
developed countries, patients often present late to medical
attention and may have HIVAN; however, this renal lesion
can develop in patients on HAART due to poor medication
adherence.
Other forms of HIV-related nephropathies like HIVICK
(HIV immune-complex kidney disease), HIV thrombotic
microangiopathy, as well as kidney disease associated with
opportunistic infections such as cytomegalovirus, mycobac-
terium, cryptosporidium and malignancies such as lym-
phoma and Kaposi’s sarcoma are described [11–14]. Hepati-
tis B and hepatitis C infections have an increased prevalence
intheHIV-positivepopulationandcausevariousglomerular
lesions. They also merit special mention because of the
complexity of diagnosis and management of renal disease
in the setting of combined HIV-HCV infection as well as
its increased mortality risks [15–17]. Additionally, HAART
and drugs used to treat opportunistic infections may cause
renal disease. Thus, the vast etiologic spectrum of renal
disease in HIV-infected patients is daunting, and HAART
nephrotoxicity is a diagnosis of exclusion.
3. Epidemiology of HAART-Associated
Nephrotoxicity
AKI that develops in the setting of HIV infection typically
occurs with severe opportunistic infections, rather than
as a sole consequence of direct toxicity of antiretrovirals.
However, antiretroviral nephrotoxic eﬀects accounted for
14% of late-onset AKI episodes, occurring after 3 months of
initiating HAART [18]. AKI in hospitalized HAART na¨ ıve-
HIV-1-infected patients is associated with a 6-fold higher
risk of in-hospital mortality [19]. In the post-HAART era,
HIV-infected patients with AKI still have an increased risk of
in-hospital mortality, and these episodes of AKI seem more
frequent in the ﬁrst year of therapy [20]p r o b a b l yd u el a t e
presentation of patients and severe immunosupression with
concurrent infections at the time of admission.
HAART has also been associated with CKD. The major
drugs implicated in this include indinavir, atazanavir,
and tenofovir [21]. The Development of Antiretroviral
Therapy in Africa (DART) trial examined 3,316 symp-
tomatic ART-naive adults from Uganda and Zimbabwe
with CD4 < 200cells/mm3 who were initiated on HAART
with zidovudine-lamivudine plus tenofovir (74%), nevirap-
ine (16%), or abacavir (9%). The study concluded that
severe kidney dysfunction (<30mL/min as estimated by the
Cockcroft-Gault formula) occurred in only 2.7% of patients
on all regimens and kidney disease contributed to death
in a minority of patients, which was generally related to
concurrent disease [22]. The major limitation was that renal
tubular function was not assessed.
Although a low incidence (0.3 to 2%) is noted [23],
tenofovir (TDF) is the drug most often associated with
Fanconi syndrome (FS) [24], which carries the potential
consequences of calcium and phosphorus dysregulation and
osteomalacia [25, 26]. In a meta-analysis of 17 studies
(including 9 randomized, controlled trials) examining TDF
safety, a signiﬁcantly greater loss of kidney function among
the TDF recipients, compared with control subjects (mean
diﬀerence in calculated creatinine clearance, 3.92mL/min;
95% conﬁdence interval [CI], 2.13–5.70mL/min), as well as
a greater AKI risk (risk diﬀerence, 0.7%; 95% CI, 0.2–1.2),
was noted [27].
4.RiskFactorsAssociatedwithDrug-Induced
Nephrotoxicicity
Risk factors for nephrotoxicity are numerous and depend
on underlying patient characteristics as well as the drug
regimen under consideration. Traditional risk factors for
kidney disease like hypertension, diabetes mellitus, and use
of other nephrotoxic agents remain signiﬁcant concerns in
HIV patients on HAART [5, 28]. A number of observational
studieshavedocumentedTDF-associatednephrotoxicityfol-
lowingitswidespreaduseinpatientswithmultiplecomorbid
conditions [22]. TDF-induced renal toxicity is more likely
to occur in HIV patients with preexisting kidney disease or
poorly controlled HIV disease with longer overall antiviral
treatment duration, older age, elevated baseline creatinine
concentration, female gender, African American ethnicity,
CD4 nadir <200cells/mm3, and concomitant administration
of other nephrotoxic drugs [29, 30]. Combined therapy
with TDF and protease inhibitors such as ritonavir appears
to increase renal toxicity [31]. Conversely, HAART may
increasetheriskofhypertension,diabetesmellitus,andother
metabolic complications creating a vicious cycle.
In a study by Wyatt et al., the major risk factors for AKI
and associated mortality included severe immunosupression
(CD4 count, <200cells/mm3) and opportunistic infections
[19]. Dehydration, alkaline urine, and a previous history
of nephrolithiasis appear to be risk factors for atazanavir-
associated kidney stones [32].
The risk factors for hyperlactemia (lactate > 2mmol/L
with or without acidosis) which is common with “d-drugs”
like stavudine (d4T) and didanosine (ddI) include extended
duration of treatment, old age, female gender, pregnancy,
hypertriglyceridemia,obesity,hepatitisCinfection,impaired
kidney function, treatment with ribavirin, and alcohol use
[33, 34].
5. ClinicalandPathological Presentationof
HAART-RelatedKidney Disorders
Clinically, HAART causes various kidney syndromes includ-
ing various electrolyte and acid-base disorders, AKI, lactic
acidosis, and chronic kidney disease. These injuries occur
via multiple mechanisms, including direct tubular toxicity,
allergicreactions,andprecipitationofinsolubledrugcrystals
within renal tubular lumens [35].
There are more than 20 drugs available on the market
today for HIV treatment with the ﬁrst-line therapies varyingAIDS Research and Treatment 3
Table 1: Preferred ﬁrst-line ART in treatment of naive adults and
adolescents.
Target Population Preferred option
A d u l t sa n da d o l e s c e n t sA Z To rT D F+3 T Co rF T C+E F Vo rN V P
Pregnant women AZT + 3TC + EFV or NVP
H I V / T Bc o i n f e c t i o n A Z To rT D F+3 T Co rF T C+E F V
HIV/HBV coinfection TDF + 3TC or FTC + EFV or NVP
Zidovudine (AZT), tenofovir (TDF), lamivudine (3TC), emtricitabine
(FTC), nevirapine (NVP), and efavirenz (EFV). Source: WHO, 2010.
across the globe. Most of the ﬁrst-line therapies include
nucleos(t)ide reverse transcriptase inhibitors (NRTI) with
either a protease inhibitor (PI) or a nonnucleoside reverse
inhibitor(NNRTI).Table 1 notesthepreferredﬁrst-lineARV
regimens by the WHO [36].
However, it is important to note that the choice of
the nucleoside backbone depends on the patient’s clini-
cal and virological proﬁle. For example, a baseline viral
load >100,000copies/mL makes a tenofovir-based regimen
preferable over abacavir [37]. Patients with baseline kidney
dysfunction may also beneﬁt from the tenofovir-sparing
regimen when such resources are available. However, the
optimal glomerular ﬁltration rate at which such a decision
should be made is largely unknown. On the other hand,
patients with HIV/HBV coinfection will require tenofovir
plus lamivudine or emtricitabine as the backbone [36]. In
such patients, the GFR should be estimated and the HAART
dose should be adjusted accordingly. Of note, nucleoside-
sparing regimens should be used with caution in patients
with protease-resistant HIV viral isolates [38].
6.AcuteKidney InjuryRelatedto Medications
Studies of AKI occurring in HIV-infected individuals have
demonstrated that medications commonly employed to the
treatment of HIV-related infections are important causes of
kidney injury including ATN. Aminoglycoside antibiotics,
pentamidine, acyclovir, foscarnet, amphotericin, tenofovir,
adefovir, and cidofovir have all been associated with ATN in
HIV-infected patients [39].
The possibility of rhabdomyolysis with pigment-related
kidney injury should be considered in patients with HIV
who develop AKI, particularly if they are being treated
with zidovudine, didanosine, or integrase inhibitors [40–
42]. In one renal biopsy series of European patients with
HIV, approximately 10% of AKI cases were attributed to
myoglobinuric pigment nephropathy [43].
Tenofovir, which is commonly used in combination with
emtricitabine (FTC) as Truvada or as a single pill contain-
ing efavirenz/emtricitabine/tenofovir disoproxil fumarate
(Atripla) [46], is widely prescribed and is an integral part
of each of the four “preferred” regimens for treatment
of HIV-1 in antiretroviral-naive adults and adolescents
[47]. This popularity has largely been attributed to its
convenient dosing schedule, antiviral eﬃcacy, and relatively
favourable side-eﬀect proﬁle, making it one of the most
widely prescribed antiretroviral drugs for the treatment of
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Figure 1: Tenofovir is predominantly eliminated via a combination
of glomerular ﬁltration and active tubular secretion. It enters
into the kidney cell from the basolateral side via organic anion
transporters, OAT-1 and OAT-3 [44], and leaves either via P
glycoprotein, MRP2, and/or MRP4 [45]. Inhibition of MRP4 by
PI/RTV leads to increased intracellular tenofovir levels which may
increase its nephrotoxic eﬀects. OAT: organic anion transporter;
MRP: multidrug resistant protein; PI/RTV: ritonavir-boosted pro-
tease inhibitor; TFV: tenofovir.
HIV-1 [48]. The TDF/FTC combination is rapidly becoming
popular even in resource-limited settings, especially with
eﬀorts to phase out the more toxic stavudine. TDF/FTC use
is also likely to increase for post-HIV exposure prophylaxis
andaspartoftreatmentofchoiceforHIVpatientscoinfected
with hepatitis B virus [36, 49]. The recent preexposure trial
and interim guidelines by the CDC on the use of TDF/FTC
in men who have sex with men make this drug even more
important [50, 51].
Ritonavir-boosted PIs may have an increased propensity
of causing renal injury. Approximately 70% of the published
cases of TDF-induced nephrotoxic eﬀects are observed
with concomitant use of low-dose ritonavir. An interaction
between lopinavir-ritonavir combination therapy and TDF,
which manifests as a decrease in the renal clearance of TDF,
has been identiﬁed [52]. TDF is actively taken up into the
proximal tubules and secreted into the lumen via multidrug
resistance-associated protein-4 [45]. Inhibition of MRP4 by
PI/RTV leads to increased intracellular tenofovir levels that
may increase its nephrotoxicity eﬀects [45, 53] (see detailed
mechanism in Figure 1).
Postmarketing safety data covering 455,392 person-years
of TDF exposure showed serious renal adverse events in
only 0.5% of patients and graded elevations in serum
creatinine in 2.2% of patients (Nelson, MR). With time,
TDF has been linked to the development of proximal tubular
dysfunction including Fanconi syndrome (FS), AKI, nephro-
genic diabetes insipidus (NDI), and severe hypokalemia
[24, 31, 54–56]. Lamivudine, stavudine, abacavir, and
didanosine have also been implicated in case reports of
FS and NDI [30, 57, 58]. Fanconi syndrome caused by
tenofovir-induced nephrotoxicity is characterized by gener-
alized proximal tubular dysfunction resulting in one or more
of the following: bicarbonaturia, glucosuria (with normal
blood sugar), phosphaturia, uricosuria, aminoaciduria, and
tubular proteinuria. It is hypothesized that this toxicity is4 AIDS Research and Treatment
the result of mitochondrial DNA depletion or direct tubular
cytotoxicitysimilartothatassociatedwiththeuseofadefovir
and cidofovir [31, 59–61]. Most of these adverse reactions
can be reversed with discontinuation of the drug, although
some will not be completely reversed [62]. A recent study
by the Columbia University group demonstrated that TDF
nephrotoxicity is manifested as toxic acute tubular necrosis
targeting proximal tubules (including FS in some cases) and
manifests distinctive light microscopic and ultrastructural
features of mitochondrial injury [63]. While all patients
recovered kidney function, including discontinuation of
dialysis, nearly half were left with some level of CKD.
One limitation when assessing nephrotoxicity of TDF is
the relatively short “96-week” followup in clinical trials, as
Fanconi syndrome may occur after a relatively long time of
tenofovir treatment.
In a forty-eight-week multicenter randomized trial
comparing abacavir/lamivudine to TDF/FTC for adverse
renal eﬀects, eﬃcacy, and safety in HAART-na¨ ıve patients
(ASSERT study), there was no diﬀerence in estimated
glomerular ﬁltration rate between the arms [64]. However,
increases in markers of tubular dysfunction were observed
in the TDF/FTC arm, the long-term consequence of which
is unclear. A signiﬁcant diﬀerence in eﬃcacy that favored
TDF/FTC wasalso observed [64].Abacavir/lamuvudine is an
alternative combination to TDF/FTC.
The clinical implications of TDF use are unclear, but
clinicians should routinely evaluate for FS and other nephro-
toxicity in patients on this drug. In general, the beneﬁcial
immunological and virological responses gained with TDF
largely outweigh potential renal toxicity.
Acute interstitial nephritis (AIN) has been described
with indinavir, abacavir, ritonavir, and atazanavir [65–67].
In addition to ARVs, other drugs used for prophylaxis and
treatment of opportunistic infections in HIV-AIDS patients,
such as trimethoprim/sulfamethoxazole, amphotericin B,
acyclovir, and antituberculous drugs like rifampicin, strep-
tomycin, and pyrazinamide have been associated with AKI.
Nonsteroidal anti-inﬂammatory drugs (NSAIDs), trimetho-
prim/sulfamethoxazole, and rifampin may cause acute inter-
stitial nephritis in HIV-infected patients [68]. NSAIDS may
also promote prerenal azotemia in patients with true or
eﬀective intravascular volume depletion. Abacavir causes
renal toxicity as part of the systemic clinical syndrome
of abacavir hypersensitivity, which can be avoided by the
HLA-B∗ 5701 screening [69]. AIN often resolves with drug
discontinuation, but steroid therapy in severe biopsy-proven
cases may be beneﬁcial when employed early.
In clinical trials, AKI has been reported to occur in 1% of
patients assigned to etravirine [70]. In two randomized trials
(DUET-1 and DUET-2) examining the eﬃcacy and safety of
etravirine in treatment of experienced HIV-1 patients, renal
failure was rare and similar in both arms underscoring the
goodrenaltolerancetoetravirineinHIV-pretreatedpatients.
Etravirine in combination with darunavir/ritonavir further
widens the choice of antiretroviral therapy in treatment
experienced patients with renal disease [71–73].
Urinary obstruction and AKI may develop secondary
to stones associated with drugs such as sulphadiazine,
acyclovir, indinavir, atazanavir, and rarely trimethoprim-
sulfamethoxazole, particularly in patients with underlying
riskfactors[74–76].Inacasereport, efavirenzhasbeenasso-
ciated with minimal change disease from podocyte injury
as well as urolithiasis [77]. Proper volume resuscitation may
reduce or reverse stone formation, but the drug may need to
be discontinued in some cases [78]. Immune reconstitution
inﬂammatory syndrome (IRIS) which commonly occurs
within the ﬁrst three months of starting HAART has also
been associated with AKI. Clinicians should include it
as a diﬀerential diagnosis of nephrotoxic eﬀect of some
antiretrovirals [79, 80].
A selected list of drugs associated with acute kidney
injury is shown in Table 2.
7.ChronicKidney Disease
The Infectious Disease Society of America recommends that,
at the time of HIV diagnosis, all patients should be assessed
for evidence of CKD, and, if present, be appropriately
staged for kidney disease. The best way to measure the GFR
involves administering a foreign substance like inulin or
radio-isotopes that the glomeruli will ﬁlter completely as
waste, without reabsorption by the tubules, and measuring
itsclearanceovertime[81,82].Unfortunately,thesemethods
are quite expensive and too complex to use outside the
research setting. The 24-hour creatinine clearance is also
laborious and awkward, but it has been validated in a small
study of HIV-positive patients [83].
Most nephrologists believe that the use of serum crea-
tinine measurement alone is an insensitive measurement of
GFR for all patients and other estimation formulas should be
used.
In clinical practice, creatinine-based equations, such as
the Cockcroft-Gault (CG) equation that estimates creati-
nine clearance, the Modiﬁcation of Diet in Renal Disease
(MDRD), and Chronic Kidney Disease Epidemiology Col-
laboration (CKD-EPI) equations, both which estimate GFR,
are used to assess kidney function [78, 84]. The choice of
the equation to be used to measure renal impairment is
still under contention, but the CKD-EPI equation has been
reportedtobemoreaccuratethantheMDRDstudyequation
overallandacrossmostsubgroups[84].Thelimitationofthe
Cockcroft equation is that the muscular mass is estimated by
age and weight, which can be misleading in some situations
including old age and obesity. In one cross-sectional study
to determine the best method for estimating the GFR in
HIV-infected subjects, isotopic GFR was correlated with 24-
hour urine creatinine clearance, cystatin C levels, and 3
creatinine-based equations, the MDRD, CG, and CKD-EPI
in 15 patients. Cystatin C showed the strongest correlation
with isotopic GFR (r =− 0.760, P = 0.001). When
cystatin C was used as the reference variable for all 106
patients, CKD-EPI proved to be superior to the other
equations (r =− 0.671, P<0.001) [85]. However, all these
equationshavediminishedaccuracyatestimatingGFRabove
60mls/min/1.73m2 [86, 87].AIDS Research and Treatment 5
Table 2: Selective drugs causing AKI in HIV-infected patients.
Drugs
Acute tubular
injury (ATI) or
AKI
Acute
interstitial
nephritis
Other associated abnormalities
TMP-SMX (Bactrim) +++ Hyperkalemia, crystalluria
β-lactams ++
Sulfadiazine ++ Crystalluria, nephrolithiasis
Fluoroquinolones +
Rifampin ++Hypokalemia, hypouricemia, hypernatremia, vasculitis
INH + Overdose leads to high anion gap metabolic acidosis
NSAIDs +/− + Proteinuria, secondary minimal change disease, papillary necrosis
Dapsone +/− Papillary necrosis
Amphotericin B +++ Hypokalemia, hypomagnesemia, hypernatremia, NDI
Pentamidine +++ Crystalluria, hyperkalemia
Foscarnet +++ Hypercalcemia/hypernatremia, Glomerular crystals
Ganciclovir +
Acyclovir ++ /− Crystalluria
Indinavir, atazanavir + Crystalluria, nephrolithiasis
Abacavir +/−
Tenofovir ++ Fanconi, NDI
Key: + mild, ++ moderate, +++ severe injury. NDI: nephrogenic diabetes insipidus.
Early studies evaluating the accuracy of Cockcroft-Gault
equation in HIV patients yielded conﬂicting results and did
not use inulin or radioisotope clearance as gold standards
[88, 89]. In Ghana and South Africa, these formulae were
not accurate and the adjustments made to the equations
to account for race in the MDRD equation made the
estimations less reliable [90, 91]. The jury is still out for the
best method of estimating GFR in HIV patients as well as
those of diﬀerent ethnicities.
The use of other potential indicators of kidney injury
(biomarkers) among HIV-positive individuals like retinol
binding protein (RBP), N-acetyl-beta-D-glucosaminidase
(NAG), and neutrophil gelatin-associated lipocalin (NGAL)
have been studied as indicators of kidney injury. While
NGAL indicates glomerular or proximal tubular dysfunc-
tion, RBP and NAG may reﬂect proximal renal tubular
dysfunction [92–94]. Patients on tenofovir without evidence
of proteinuria by dipstick have been demonstrated to have
higher levels of urinary RBG excretion [95].
Itisoftenchallengingtodistinguishantiretroviral-related
renal toxicity from either direct eﬀects of HIV-1 on the
kidney or from a multitude of non-HIV-related kidney
diseases [22]. In many patients, severe GFR decreases may
simply be primarily a reﬂection of acute intercurrent illness
rather than ongoing drug nephrotoxicity. The scenario is
further complicated by the fact that HIV-AIDS patients are
now living longer and are more predisposed to age-related
chronic diseases [68].
Chronic kidney diseases due to diabetes mellitus, hyper-
tension, renovascular disease, and chronic glomerulonephri-
tis are on the rise, and these contribute to kidney dys-
function, sometimes through drug interactions [96]. These
diseases are likely to be missed if they are not actively
searched for in the HIV programs. Tenofovir has also been
associated with osteoporosis which may have far reaching
consequences in patients with preexisting CKD and its
antecedent bone-mineral disorders [97]. For patients with
bone-mineral disorders, phosphatemia should be analyzed
in a fasting patient, and vitamin D should be assessed when
interpreting hypophosphatemia.
8. Recommendations for HAARTUse in
PatientswithKidney Disease
The evaluation of an HIV-infected patient with suspected
kidney disease should follow the usual guidelines utilized
for non-HIV-infected patients. AKI should be approached
with the usual practice of looking for prerenal, renal, and
postrenal causes. The common causes of AKI in the HIV-
patient should be actively sought and addressed. Before
starting antiretroviral treatment, all patients should be
screened for kidney disease according to the Infectious
Disease Society of America guidelines [78]. For patients
to be initiated on drugs known to cause nephrotoxicity,
renal function tests should routinely be performed. This
may help to prevent development of CKD, which would
require further resource utilization [98]. It is also important
to remember that many patients with HIV may present
with muscle wasting while receiving HAART, which can
lower serum creatinine concentration and falsely support the
presence of normal kidney function. In such patients, serum
creatinine measurement alone is an insensitive measurement
of GFR. Conversely, with HAART therapy patients may gain
weight, and creatinine may increase without renal injury.6 AIDS Research and Treatment
Table 3: Dose adjustment for commonly used NRTIs.
Agent Normal dose Estimated GFR (creatinine clearance: CrCl)
Zidovudine 300mg twice a day orally 100mg thrice a day orally
Lamivudine 150mg twice a day orally
30–49mL/min = 150mg once a day orally
15–29mL/min = 100mg once a day orally
5–14mL/min = 50mg once a day orally
<5mL/min = 25mg once a day orally
Stavudine 30mg twice a day orally 26–50mL/min = 15mg twice a day orally
<26mL/min = 15mg once a day orally
Didanosine >60kg: 200mg twice a day orally
<60kg, 125mg twice a day orally
30–59mL/min = 200mg once a day orally
10–29mL/min = 150mg once a day orally
<10mL/min = 100mg once a day orally
30–59mL/min = 150mg once a day orally
10–29mL/min = 100mg once a day orally
<10mL/min = 75mg once a day orally
Tenofovir 300mg once a day orally
30–49mL/min = 300mg every second day
10–29mL/min = 300mg every third day
<10mL/min = 300mg once weekly
(Note: no dose adjustment necessary for abacavir).
Clinicians should therefore make appropriate adjust-
ments in drug dosage based on the patient’s estimated
creatinine clearance as calculated by the Cockcroft-Gault
equation or estimated GFR (MDRD, CKD-EPI formulae).
The selected regimen should be dose adjusted based on the
established guidelines using the estimated GFR and stage of
kidney disease.
MostNNRTIs,PIs,fusioninhibitors,integraseinhibitors,
and CCR5 antagonists do not require dose modiﬁcation in
CKD or ESRD. However, several drugs need special mention
because of their increased use and/or demonstrated adverse
eﬀects on the kidneys. The usual dosage of TDF for HIV
patients without signiﬁcant renal insuﬃciency is 300mg
daily, but it requires dose adjustments at creatinine clearance
(CrCl) levels below 50mL/min as indicated in Table 3.
Combination therapy such as TDF/FTC (300mg
TDF/200mg FTC) also requires dose adjustments for
CrCl of 30–49mL/min. Most importantly, the TDF/FTC
combination pill is not recommended for patients with
CrCl below 30mL/min. Clinicians may therefore opt to
prescribe TDF as a separate drug that is renally adjusted, in
combination with other HAART regimens. Alternatively,
due to the current lack of concrete data, countries with
safer alternative regimens can avoid this drug when the GFR
drops below 50mL/min. Along these lines, several studies
have demonstrated irreversible renal injury beyond one year
[62, 63, 99].
There is also signiﬁcant drug interaction between TDF
and DDI. Thus, when coadministered with TDF, it is impor-
tant to make appropriate reduction in dose adjustments of
DDIinpatientsweighing60kilogramsormore[78].Because
the potential toxic interactions between TDF and DDI as
well as the lack of immunological eﬃcacy, this combination
should be avoided.
Indinavir (800mg twice daily) can cause dysuria, ﬂank
pain, renal colic, hematuria, crystalluria, nephrolithiasis,
AKI, CKD, and papillary necrosis and has largely been
supersededbynewerandmoreeﬃcaciousPIs-likedarunavir.
One could also argue for a switch of the patients on this drug
to newer agents due to the high rates of nephrotoxicity and
the high daily ﬂuid intake requirements once on this drug
[78].
Upon HIV diagnosis, patients should be assessed for
preexistingkidneydiseasebyuseofurinalysisandcalculation
of estimated GFR; patients with 1+ proteinuria or GFR
<60mL/min/1.73m2 should be referred to a nephrologist.
Patients with diabetes must be tested for microalbuminuria
(albumin to creatinine ratio 30–300mg/mg), a range not
detected using conventional urine dipsticks. Additional
evaluations (e.g., quantiﬁcation of proteinuria and renal
ultrasonography) should be implemented on a case-by-case
basis. Patients at high risk of kidney disease (i.e., black
patients, patients with CD4+ T-cell count <200cells/mm3,
HIV RNA levels >4,000copies/mL, diabetes, hypertension,
or HCV coinfection) should be screened at least annually
for subtle changes in renal parameters; patients on TDF may
require monitoring every 3 months [78, 100].
A kidney biopsy is recommended for patients with
unexplained kidney disease, especially those with heavy
proteinuria or reduced GFR, because they are at the greatest
risk of ESRD. The kidney biopsy is also very important in
conﬁrming the diagnosis of kidney injury, which is often
quite diverse and unpredictable in HIV. As already noted
above, tenofovir toxicity can also be diagnosed on biopsy
[63]. Since kidney biopsies can be performed safely in HIV
patients, they should be employed in the proper setting.
For example, a single-center study of kidney biopsy safety
conﬁrmed that the incidence of complications related to
percutaneous ultrasound-guided kidney biopsy was similar
between HIV-positive and HIV-negative patients [101].
However, patients with HIV-hepatitis C coinfection were
at a higher risk of biopsy-related complications comparedAIDS Research and Treatment 7
with individuals infected with HIV or hepatitis C alone.
This biopsy-related increased risk should be explained to
individuals who are HIV-HCV coinfected.
Early referral of CKD patients to clinicians skilled in
management of kidney disease may improve patient out-
comes. Patients who progress to ESRD should be managed
with the available modes of renal replacement therapy (RRT)
in the country. All modes of RRT should be available for
HIV-infected patients with end-stage renal disease. Although
HIV-infected patients managed with peritoneal dialysis
had worse outcomes in pre-HAART era [102], currently
the choice of dialysis modality between hemodialysis and
peritoneal dialysis is not a factor in predicting survival, if
patients are stable on HAART [103].
Patients with HIV and ESRD can receive kidney trans-
plants. Renal transplantation is both safe and eﬀective
in HIV patients who meet established criteria. Although
rejection rates are higher in these patients, these rejections
respond well to therapy. Several drug interactions between
HAART and immunosuppressants exist and should be taken
into consideration when devising the immunosupression
regimens [104]. In a carefully selected population of patients
on HAART with CD4+ T-cell counts of at least 200 per
cubic millimeter and undetectable plasma HIV type 1 (HIV-
1) RNA levels, both patient- and graft-survival rates were
high at 1 and 3 years, with no increases in complications
associated with HIV infection. However, there was an
unexpectedly high rejection rate especially in patients who
received antithymocyte globulin induction therapy. The
authors expressed a need for better immunotherapy in these
patients [105]. There is also concern of drug interactions
between protease inhibitors and calcineurin inhibitors, and
the degree to which each aﬀects the other has important
implications with regard to organ rejection as well as
viral suppression [106, 107]. Thus, patients require vigilant
monitoring of drug interactions. Some experts have argued
for transplant of HIV-infected patients with kidneys from
HIV-infected donors following the ground breaking kidney
transplant from an HIV-positive donor in South Africa
[108]. This has been successful in four patients followed up
for 12 months [109].
9. Conclusion
HAART and other medical therapies for HIV-related infec-
tions have been associated with both short- and long-term
toxicities including nephrotoxicity. Antiretroviral therapy
can contribute to renal dysfunction directly by inducing
acute tubular necrosis, acute interstitial nephritis, crystal
nephropathy and renal tubular disorders or indirectly via
drug interactions. Kidney abnormalities tend to develop in
the setting of multiple treatments and cannot be always
attributed to a speciﬁc drug. Renal function should therefore
be monitored on a regular basis in patients with HIV receiv-
inganyantiretroviralagent.WiththeincreaseinHAARTuse,
cliniciansmustscreenpatientsforthedevelopmentofkidney
disease especially if the regimen employed increases risk of
kidney injury. It is also important that patients with CKD
are not denied the best combinations, especially since most
drugs can be adjusted based on the estimated GFR. Early
detection of risk factors, systematic screening for chronic
causes of CKD, and appropriate referrals for kidney disease
managementshouldbeadvocatedforimprovedpatientcare.
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